Decreased SUV39H1 at the promoter region leads to increased CREMα and accelerates autoimmune response in CD4+ T cells from patients with systemic lupus erythematosus

Table 1 Patient profiles

Patient	Gender	Age (years)	SLEDAI	Medications
1	Female	21	5	Pred 30 mg/d
2	Female	26	8	Pred 40 mg/d, TG 30 mg/d
3	Female	25	6	Pred 20 mg/d, HCQ 0.2 g/d
4	Female	40	11	Pred 40 mg/d, CsA 150 mg/d
5	Female	34	9	Pred 40 mg/d
6	Female	27	3	None
7	Female	25	2	Pred 5 mg/d
8	Female	20	8	Pred 20 mg/d, MMF 1.5 g/d, HCQ 0.2 g/d
9	Male	25	12	None
10	Female	36	14	Pred 15 mg/d
11	Female	35	8	Pred 40 mg/d
12	Female	33	3	Pred 5 mg/d, HCQ 0.2 g/d
13	Female	25	16	Pred 50 mg/d, MMF 1.5 g/d
14	Male	24	2	Pred 30 mg/d
15	Female	23	12	Pred 35 mg/d, TG 30 mg/d
16	Female	36	16	Pred 40 mg/d, TG 30 mg/d, HCQ 0.2 g/d
17	Female	32	6	None
18	Female	27	4	None
19	Female	23	15	Pred 50 mg/d, CsA 150 mg/d
20	Female	31	7	Pred 30 mg/d, HCQ 0.2 g/d

SLEDAI, systemic lupus erythematosus disease activity index; Pred, prednisone; TG, tripterygium glycoside; HCQ, hydroxychloroquine; CsA, cyclosporin A; and MMF: mycophenolate mofetil

ISSN: 1868-7083